Nurix Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Greg Renza - RBC Capital Markets - Analyst : That's great. Certainly that's the area of our and investor focus, especially with the BTK target. Other pieces of Nurix really going on in the background is the foundation of your platform and just realizing value through collaborations and partnerships. So maybe before we get to 2127 and those in the clinic, maybe just walk us through your collaboration strategy, certainly thinking about your recent collab with Gilead in the IRAK4 for inflammatory diseases. So what can you tell us about the company philosophy for partnering with a large pharma and biotech?

Question: Greg Renza - RBC Capital Markets - Analyst : And as you mentioned it, providing the validation also, may be some financial security from Nurix is in. Just curious, as these opt-ins come -- you mentioned Gilead and Sanofi -- how is this informing your strategy for additional collaborations or for deepening those relationships? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. MAY 17, 2023 / 8:35PM, NRIX.OQ - Nurix Therapeutics Inc at RBC Capital Markets Global Healthcare Conference

Question: Greg Renza - RBC Capital Markets - Analyst : That's great. So maybe we can now just focus on what's in the clinic and turn to 2127. And that program's certainly an important resistance story to tell. What's the mechanistic rationale of pairing BTK and IMiD when it comes to the activity coming out of 2127?

Question: Greg Renza - RBC Capital Markets - Analyst : Yeah. And certainly last year with -- thought it was in May for your R&D Day and leading into that to the rest of the years, as you're mentioning, some consistent activity with 2127. And then of course, the continual flow of preclinical characterization from AACR this year. But eyes will be turning, of course, to some of the data updates for later this year. Maybe just help frame that up for us, maybe setting some expectations on what those data updates could look like, as we will be looking towards the back half of 2023?

Question: Greg Renza - RBC Capital Markets - Analyst : Great. And maybe on 5948, just walk us through some of the differentiation points, attributes of blood-brain barrier crossing, and how we compare and contrast both assets.

Question: Greg Renza - RBC Capital Markets - Analyst : Yeah, that's certainly very exciting. And just with the growing data packages in 2127, with the initial readouts from 5948, what are you learning about BTK degradation that maybe differentiates from others in the space? And we're seeing more coming online. There are still several shortfalls. We're talking about the resistance. There's also the later onset anti-tumor activity, the AFib and bleeding risks. So how are your assets positioned to maybe navigate those shortcomings?

Question: Greg Renza - RBC Capital Markets - Analyst : Yeah. Another event that folks are watching is just your interfaces with the regulators. What is the latest on FDA understanding the potential feedback about really what could be the nearest term or paths to market with 2127?

Question: Greg Renza - RBC Capital Markets - Analyst : Great. And maybe we can just close by asking on 1607. Just on the CBL program, just the specific data points that you'll be looking for to determine next steps and how that will be advancing in combo.

Question: Greg Renza - RBC Capital Markets - Analyst : Yeah. That's great. And maybe we will just close this on your resourcing and that runway, having mentioned of course, the inflows that you receive from your collabs, how far can your current cash and resource position take you?

Question: Greg Renza - RBC Capital Markets - Analyst : Great. Well, we can leave it there. Arthur, great to see you. Congrats on the progress and look forward to tracking the developments.